Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Giuseppe Roscilli is active.

Publication


Featured researches published by Giuseppe Roscilli.


Journal of Medicinal Chemistry | 2009

Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors.

Philip Jones; Sergio Altamura; Julia K. Boueres; Federica Ferrigno; Massimiliano Fonsi; Claudia Giomini; Stefania Lamartina; Edith Monteagudo; Jesus M. Ontoria; Maria Vittoria Orsale; Maria Cecilia Palumbi; Silvia Pesci; Giuseppe Roscilli; Rita Scarpelli; Carsten Schultz-Fademrecht; Carlo Toniatti; Michael Rowley

We disclose the development of a novel series of 2-phenyl-2H-indazole-7-carboxamides as poly(ADP-ribose)polymerase (PARP) 1 and 2 inhibitors. This series was optimized to improve enzyme and cellular activity, and the resulting PARP inhibitors display antiproliferation activities against BRCA-1 and BRCA-2 deficient cancer cells, with high selectivity over BRCA proficient cells. Extrahepatic oxidation by CYP450 1A1 and 1A2 was identified as a metabolic concern, and strategies to improve pharmacokinetic properties are reported. These efforts culminated in the identification of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide 56 (MK-4827), which displays good pharmacokinetic properties and is currently in phase I clinical trials. This compound displays excellent PARP 1 and 2 inhibition with IC(50) = 3.8 and 2.1 nM, respectively, and in a whole cell assay, it inhibited PARP activity with EC(50) = 4 nM and inhibited proliferation of cancer cells with mutant BRCA-1 and BRCA-2 with CC(50) in the 10-100 nM range. Compound 56 was well tolerated in vivo and demonstrated efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer.


Human Gene Therapy | 2002

Stringent control of gene expression in vivo by using novel doxycycline-dependent trans-activators.

Stefania Lamartina; Giuseppe Roscilli; Cira Daniela Rinaudo; Elisabetta Sporeno; Luisa Silvi; Wolfgang Hillen; Hermann Bujard; Riccardo Cortese; Gennaro Ciliberto; Carlo Toniatti

The tetracycline (Tet)-dependent regulatory system has been widely used for controlling gene expression. The Tet-on version of the system, in which the reverse Tet-responsive transcriptional activator (rtTA) is positively regulated by Tet or its analogs, such as doxycycline (Dox), is of potential utility for gene therapy applications in humans. However, rtTA may display a high basal activity, especially when delivered in vivo by using episomal vectors such as plasmids. Two novel Dox-inducible activators, called rtTA2(S)-S2 and rtTA2(S)-M2, which have a significantly lower basal activity than rtTA in stably transfected cell lines, have been described. In this study we tested the capability of these trans-activators to control expression of mouse erythropoietin (mEpo) and to modulate hematocrit (Hct) increase in vivo on delivery of plasmids into quadriceps muscles of adult mice by DNA electroinjection. Both rtTA2(S)-M2 and rtTA2(S)-S2 displayed a considerably lower background activity and higher window of induction than rtTA in vivo. Moreover, a stringent control of mEpo gene expression and Hct levels in the absence of any background activity was maintained over a 10-month period by injecting as little as 1 microg of a single plasmid containing the rtTA2(S)-S2 expression cassette and the Tet-responsive mEpo cDNA. This constitutes the first report of a stringent ligand-dependent control of gene expression in vivo obtained by delivering a single plasmid encoding both the trans-activator and the regulated gene. Notably, the rtTA2(S)-S2-based system was induced by oral doses of doxycycline comparable to those normally used in clinical practice in humans.


Cell Death and Disease | 2013

Stearoyl-CoA desaturase-1 is a key factor for lung cancer-initiating cells

Alessia Noto; S Raffa; C De Vitis; Giuseppe Roscilli; Debora Malpicci; Pierpaolo Coluccia; A Di Napoli; Alberto Ricci; Maria Rosaria Giovagnoli; Luigi Aurisicchio; Maria Rosaria Torrisi; Gennaro Ciliberto; Rita Mancini

In recent years, studies of cancer development and recurrence have been influenced by the cancer stem cells (CSCs)/cancer-initiating cells (CICs) hypothesis. According to this, cancer is sustained by highly positioned, chemoresistant cells with extensive capacity of self renewal, which are responsible for disease relapse after chemotherapy. Growth of cancer cells as three-dimensional non-adherent spheroids is regarded as a useful methodology to enrich for cells endowed with CSC-like features. We have recently reported that cell cultures derived from malignant pleural effusions (MPEs) of patients affected by adenocarcinoma of the lung are able to efficiently form spheroids in non-adherent conditions supplemented with growth factors. By expression profiling, we were able to identify a set of genes whose expression is significantly upregulated in lung tumor spheroids versus adherent cultures. One of the most strongly upregulated gene was stearoyl-CoA desaturase (SCD1), the main enzyme responsible for the conversion of saturated into monounsaturated fatty acids. In the present study, we show both by RNA interference and through the use of a small molecule inhibitor that SCD1 is required for lung cancer spheroids propagation both in stable cell lines and in MPE-derived primary tumor cultures. Morphological examination and image analysis of the tumor spheroids formed in the presence of SCD1 inhibitors showed a different pattern of growth characterized by irregular cell aggregates. Electron microscopy revealed that the treated spheroids displayed several features of cellular damage and immunofluorescence analysis on optical serial sections showed apoptotic cells positive for the M30 marker, most of them positive also for the stemness marker ALDH1A1, thus suggesting that the SCD1 inhibitor is selectively killing cells with stem-like properties. Furthermore, SCD1-inhibited lung cancer cells were strongly impaired in their in vivo tumorigenicity and ALDH1A1 expression. These results suggest that SCD1 is a critical target in lung cancer tumor-initiating cells.


Journal of Gene Medicine | 2007

Helper-dependent adenovirus for the gene therapy of proliferative retinopathies: stable gene transfer, regulated gene expression and therapeutic efficacy

Stefania Lamartina; Monica Cimino; Giuseppe Roscilli; Ernesta Dammassa; Domenico Lazzaro; Rossella Rota; Gennaro Ciliberto; Carlo Toniatti

Ocular neovascular disorders, such as diabetic retinopathy and age‐related macular degeneration, are the principal causes of blindness in developed countries. Current treatments are of limited efficacy, whereas a therapy based on intraocular gene transfer of angiostatic factors represents a promising alternative. For the first time we have explored the potential of helper‐dependent adenovirus (HD‐Ad), the last generation of Ad vectors, in the therapy of retinal neovascularization.


PLOS ONE | 2011

Spheres Derived from Lung Adenocarcinoma Pleural Effusions: Molecular Characterization and Tumor Engraftment

Rita Mancini; Enrico Giarnieri; Claudia De Vitis; Donatella Malanga; Giuseppe Roscilli; Alessia Noto; Emanuele Marra; Carmelo Laudanna; Pietro Zoppoli; Pasquale De Luca; Andrea Affuso; Luigi Ruco; Arianna Di Napoli; Giuseppe Mesiti; Luigi Aurisicchio; Alberto Ricci; Salvatore Mariotta; Lara Pisani; Claudio Andreetti; Giuseppe Viglietto; Erino A. Rendina; Maria Rosaria Giovagnoli; Gennaro Ciliberto

Malignant pleural effusions (MPEs) could represent an excellent source to culture a wide variety of cancer cells from different donors. In this study, we set up culture conditions for cancer cells deriving from MPEs of several patients affected by the most frequent form of lung cancer, namely the subset of non small cell lung cancers (NSCLC) classified as Lung Adenocarcinomas (AdenoCa) which account for approximately 40% of lung cancer cases. AdenoCa malignant pleural effusions gave rise to in vitro cultures both in adherent and/or in spheroid conditions in almost all cases analyzed. We characterized in greater detail two samples which showed the most efficient propagation in vitro. In these samples we also compared gene profiles of spheroid vs adherent cultures and identified a set of differentially expressed genes. Finally we achieved efficient tumor engraftment in recipient NOD/SCID mice, also upon inoculation of small number of cells, thus suggesting indirectly the presence of tumor initiating cells.


Journal of Virology | 2000

Conditional Site-Specific Integration into Human Chromosome 19 by Using a Ligand-Dependent Chimeric Adeno-Associated Virus/Rep Protein

Daniela Rinaudo; Stefania Lamartina; Giuseppe Roscilli; Gennaro Ciliberto; Carlo Toniatti

ABSTRACT It is of great interest for gene therapy to develop vectors that drive the insertion of a therapeutic gene into a chosen specific site on the cellular genome. Adeno-associated virus (AAV) is unique among mammalian viruses in that it integrates into a distinct region of human chromosome 19 (integration site AAVS1). The inverted terminal repeats (ITRs) flanking the AAV genome and the AAV-encoded nonstructural proteins Rep78 and/or Rep68 are the only viral elements necessary and sufficient for site-specific integration. However, it is also known that unrestrained Rep activity may cause nonspecific genomic rearrangements at AAVS1 and/or have detrimental effects on cell physiology. In this paper we describe the generation of a ligand-dependent form of Rep, obtained by fusing a C-terminally deleted Rep68 with a truncated form of the hormone binding domain of the human progesterone receptor, which does not bind progesterone but binds only its synthetic antagonist RU486. The activity of this chimeric protein, named Rep1-491/P, is highly dependent on RU486 in various assays: in particular, it triggers site-specific integration at AAVS1 of an ITR-flanked cassette in a ligand-dependent manner, as efficiently as wild-type Rep68 but without generating unwanted genomic rearrangement at AAVS1.


Journal of Cellular Physiology | 2012

Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors†

Luigi Aurisicchio; Emanuele Marra; Laura Luberto; Fabrizio Carlomosti; Claudia De Vitis; Alessia Noto; Zeynep Gunes; Giuseppe Roscilli; Giuseppe Mesiti; Rita Mancini; Maurizio Alimandi; Gennaro Ciliberto

The role of the ErbB3 receptor in signal transduction is to augment the signaling repertoire of active heterodimeric ErbB receptor complexes through activating the PI3K/AKT pathway, which in turn promotes survival and proliferation. ErbB3 has recently been proposed to be involved in acquired resistance to tyrosine kinase inhibitors (TKIs), and is therefore a promising new drug cancer target. Since ErbB3 is a kinase defective receptor, it cannot be targeted by small molecule inhibitors, whereas monoclonal antibodies may offer a viable strategy for pharmacological intervention. In this study, we have utilized DNA electroporation (DNA‐EP) to generate a set of novel hybridomas directed against human ErbB3, which have been characterized for their biochemical and functional properties and selected for their ability to negatively regulate the ErbB3‐mediated signaling pathway. In vitro, the anti‐ErbB3 antibodies modulate the growth rate of cancer cells of different origins. In vivo they show antitumoral properties in a xenograft model of human pancreatic tumor and in the ErbB2‐driven carcinogenesis genetically engineered mouse model (GEMM) for mammary tumor, the BALB/neuT. Our data confirm that downregulating the ErbB3‐mediated signals with the use of anti‐ErbB3 monoclonal antibodies is both feasible and relevant for therapeutic purposes and provides new opportunities for novel anti‐ErbB3 combinatory strategies for cancer treatment. J. Cell. Physiol. 227: 3381–3388, 2012.


Oncotarget | 2015

Epigenetic silencing of miR-145-5p contributes to brain metastasis.

Sara Donzelli; Federica Mori; Teresa Bellissimo; Andrea Sacconi; Beatrice Casini; Tania Frixa; Giuseppe Roscilli; Luigi Aurisicchio; Francesco Facciolo; Alfredo Pompili; Maria Antonia Carosi; Edoardo Pescarmona; Oreste Segatto; Greg Pond; Paola Muti; Stefano Telera; Sabrina Strano; Yosef Yarden; Giovanni Blandino

Brain metastasis is a major cause of morbidity and mortality of lung cancer patients. We assessed whether aberrant expression of specific microRNAs could contribute to brain metastasis. Comparison of primary lung tumors and their matched metastatic brain disseminations identified shared patterns of several microRNAs, including common down-regulation of miR-145-5p. Down-regulation was attributed to methylation of miR-145s promoter and affiliated elevation of several protein targets, such as EGFR, OCT-4, MUC-1, c-MYC and, interestingly, tumor protein D52 (TPD52). In line with these observations, restored expression of miR-145-5p and selective depletion of individual targets markedly reduced in vitro and in vivo cancer cell migration. In aggregate, our results attribute to miR-145-5p and its direct targets pivotal roles in malignancy progression and in metastasis.


Journal of Cellular Physiology | 2013

EMT markers in lung adenocarcinoma pleural effusion spheroid cells

Enrico Giarnieri; Claudia De Vitis; Alessia Noto; Giuseppe Roscilli; Gerardo Salerno; Salvatore Mariotta; Alberto Ricci; Pierdonato Bruno; Giuseppe Russo; Andrea Laurenzi; Maria Rosaria Giovagnoli; Gennaro Ciliberto; Rita Mancini

Epithelial‐to‐mesenchymal transition (EMT) is a process in which cells undergo a developmental switch from epithelial to mesenchymal phenotype. This process has been related to embryologic morphogenesis but also to cancer progression and metastasis. The aim of the current study was to investigate the expression of EMT‐related markers in adherent and spheroid cell cultures derived from malignant pleural effusions (MPEs) of patients affected by lung adenocarcinoma. On the basis of efficient in vitro propagation, six cases of MPEs were selected and analyzed by immunocytochemistry staining for EMT markers and by RT‐PCR for transcription factors known to orchestrate EMT. EMT markers immunostaining showed in spheroids a statistically significant correlation between the loss of E‐cadherin immunoreactivity and overexpression of N‐cadherin (P < 0.001). Likewise loss of EpCAM epithelial marker was coincident with Vimentin overexpression (P < 0.001). RT‐PCR analysis of transcription factors Snail, Slug, and Twist showed a highly variable expression, although a general trend to increase was observed. Importantly, in some selected cases it was possible to establish a precise relationship between spheroid formation, EMT switch and increased upregulation of the marker related to cancer stemness such as ALDH positivity. Therefore, MPE‐derived cell cultures, while recapitulating the heterogeneity of lung cancer, are a suitable system to study the mechanisms at the basis of EMT and to understand its relationship with the generation of cancer stem cells. J. Cell. Physiol. 228: 1720–1726, 2013.


Journal of Translational Medicine | 2014

Circulating MMP11 and specific antibody immune response in breast and prostate cancer patients

Giuseppe Roscilli; Manuela Cappelletti; Claudia De Vitis; Gennaro Ciliberto; Arianna Di Napoli; Luigi Ruco; Rita Mancini; Luigi Aurisicchio

BackgroundTumor Associated Antigens are characterized by spontaneous immune response in cancer patients as a consequence of overexpression and epitope-presentation on MHC class I/II machinery. Matrix Metalloprotease 11 (MMP11) expression has been associated with poor prognosis for several cancer types, including breast and prostate cancer.MethodsMMP11 expression was determined by immunoistochemistry in breast and prostate cancer samples. Circulating MMP11 protein as well as the spontaneous immune responses against MMP11 were analyzed in a set of breast and prostate cancer patients.ResultsIn plasma samples MMP11 protein was present in 5/13 breast cancer patients and in 1/12 prostate cancer patients. An antibody response was observed in 7/13 breast cancer patients and in 3/12 prostate cancer patients.ConclusionsThese findings further suggest MMP11 as a promising biomarker for these tumor types and a suitable target for cancer immunotherapy strategies.

Collaboration


Dive into the Giuseppe Roscilli's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Rita Mancini

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar

Alessia Noto

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar

Claudia De Vitis

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Alberto Ricci

Sapienza University of Rome

View shared research outputs
Researchain Logo
Decentralizing Knowledge